Chromos updates on progress with development of CHR-1103 for treatment of MS
BURNABY, BC, Aug. 15 /CNW/ - Chromos Molecular Systems Inc. (TSX: CHR)
has taken several significant steps in the development of its lead product
candidate, CHR-1103. A humanized monoclonal antibody, CHR-1103 is being
developed for the acute treatment of relapsing forms of multiple sclerosis
(MS). Its unique mechanism of action has the potential to reduce the severity
of a relapse in patients with MS and also stem the residual neurological
damage that often accompanies relapse and leads to progression of the disease.
Chromos recently completed its first meeting with officials from the U.S.
Food and Drug Administration (FDA). The two parties discussed Chromos'
clinical approach, proposed preclinical safety evaluation program and
manufacture of CHR-1103. Chromos is now moving forward with preclinical safety
evaluation studies in preparation for an Investigational New Drug (IND)
application in Q3 2007.
Using its proprietary ACE System, Chromos engineered a stable clonal cell
line expressing its product, CHR-1103 and transferred it to AppTec for process
development, scale up and manufacture. The ACE System demonstrated the ability
to perform well in large-scale manufacturing, validating the use of the
platform for clinical and commercial scale manufacturing of
biopharmaceuticals. The Company is now preparing to begin its preclinical
safety evaluation studies with Charles River Laboratories.
Chromos has engaged two leading MS clinicians to act as clinical
consultants for its CHR-1103 program. Lily Jung, M.D. is the Medical Director
of the Seattle Neuroscience Institute at Swedish Medical Centre in Seattle,
WA, and a clinical associate professor in Neurology at the University of
Washington Medical School. Mariko Kita, M.D. is a clinical investigator and
Director of the Virginia Mason Multiple Sclerosis Center in Seattle, WA. Drs.
Jung and Kita will advise and assist with the clinical development of CHR-1103
as it enters clinical trials.
Chromos is a biopharmaceutical company with two drug development programs
focused on inflammatory diseases and thrombotic disorders. The Company's lead
program, CHR-1103, is a humanized monoclonal antibody being developed as a
treatment for acute relapses associated with relapsing forms of multiple
sclerosis. Chromos generates revenue from its proprietary ACE System
technology to engineer production quality cell lines to manufacture
biopharmaceutical products including monoclonal antibodies. For more
information visit our website at www.chromos.com